Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 42.49 USD -0.07% Market Closed
Market Cap: 3.2B USD

Wall Street
Price Targets

KNSA Price Targets Summary
Kiniksa Pharmaceuticals Ltd

Wall Street analysts forecast KNSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KNSA is 55.81 USD with a low forecast of 48.48 USD and a high forecast of 65.1 USD.

Lowest
Price Target
48.48 USD
14% Upside
Average
Price Target
55.81 USD
31% Upside
Highest
Price Target
65.1 USD
53% Upside
Kiniksa Pharmaceuticals Ltd Competitors:
Price Targets
600201
Jinyu Bio-Technology Co Ltd
42% Downside
INCY
Incyte Corp
1% Upside
SLNO
Soleno Therapeutics Inc
136% Upside
ADCT
ADC Therapeutics SA
131% Upside
NVAX
Novavax Inc
88% Upside
SVRA
Savara Inc
64% Upside
4974
Takara Bio Inc
38% Upside
7774
Japan Tissue Engineering Co Ltd
141% Upside

Revenue
Forecast

Revenue Estimate
Kiniksa Pharmaceuticals Ltd

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 4 years is 29%.

N/A
Past Growth
29%
Estimated Growth
Estimates Accuracy
2%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Kiniksa Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KNSA's stock price target?
Price Target
55.81 USD

According to Wall Street analysts, the average 1-year price target for KNSA is 55.81 USD with a low forecast of 48.48 USD and a high forecast of 65.1 USD.

What is Kiniksa Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
29%

The compound annual growth rate of Kiniksa Pharmaceuticals Ltd's revenue for the next 4 years is 29%.

Back to Top